StockData
Nexalin Technology, Inc. logo

Nexalin Technology, Inc. (NXL) company profile

NXLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.44−0.06 (-4.00%)

Close on Nov 18, 2026Market cap $31.73MP/E –Yield –

About Nexalin Technology

Electromedical & Electrotherapeutic Apparatus, SIC 3845

Nexalin designs and creates bioelectronic neurostimulation medical devices designed to address mental health conditions including anxiety, depression, and insomnia without pharmaceutical drugs or psychotherapy. Its core technology utilizes non-invasive electrical waveforms emitted through patient headsets and clinical systems. Offerings include its original Generation 1 cranial electrotherapy stimulation unit, alongside its advanced Generation 2 SYNC clinical console and Generation 3 HALO at-home headset systems. The company also supplies single-use radio-frequency identification electrodes, patient cables, and related licensing services. Customers comprise healthcare providers and licensed medical professionals who administer treatments in clinics or prescribe devices for home use via virtual clinic platforms.

Management and operating facilities are located at the company's headquarters in Houston, Texas. Beyond its domestic presence, the company maintains international regulatory approvals and operations across several jurisdictions. Its Generation 2 medical device holds regulatory clearance in Oman and Brazil, and approval in China through the National Medical Products Administration. Furthermore, clinical trials, marketing, and distribution throughout China and neighboring territories are conducted through a Hong Kong-registered joint venture, supported by a wholly foreign-owned enterprise office in the People's Republic of China.

Summary of the business section of Nexalin Technology's latest annual report, written by StockData.

Company profile

Company

Legal name
Nexalin Technology, Inc.
Founded
2010
Headquarters
Houston, TX
Address
1776 Yorktown, Suite 550 77056
Phone
(832) 260-0222
Employees
8, Dec 31, 2025
Industry
Electromedical & Electrotherapeutic Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum llp, Marlton, New Jersey

Stock & identifiers

Ticker
NXL
Exchange
Nasdaq
IPO date
Sep 19, 2022
Shares outstanding
22M, Aug 10, 2026
Public float
$14.73M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-30 reverse, Aug 31, 2026
SEC CIK
1527352
CUSIP
65345B300
ISIN
US65345B3006
FIGI
BBG014CRDGH9
Share class FIGI
BBG014CRDHD1
EIN
27-5566468

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mark WhiteCEO, Director309,127
David OwensChief Medical Officer, Director191,252
Carolyn Hamby SheltonSr. VP - Quality - Regulatory54,000
Fleet Justin VanCFO25,000
Alan KazdenDirector119,590
Ben HuDirector381,261

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Mark White
Chief Executive Officer
$300.00K$280.00K$241.48K$18.00K$839.48K-18%
David Owens, M.D.
Chief Medical Officer
––$450.08K$50.60K$500.68K-43%
Carolyn Shelton
Senior Vice-President of Quality, Clinical and Regulatory
$300.00K$40.00K$51.18K–$391.18K+36%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 19, 2022
Offer price
$4.15
Securities offered
2,315,000
Gross proceeds
$9.61M
Exchange
Nasdaq
First trading day
Sep 16, 2022
First-day close
$2.25-45.8%
Lock-up ends (est.)
Mar 15, 2023

“We are offering 2,315,000 units at an offering price of $4.15 per unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 8 full-time employees, our CMO is a consultant and we utilize varying levels of other consultants.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?